This Best Stock is the Salesforce of drug discovery. Time to get long here

Veeva Systems (VEEV) is highlighted as a critical enabler for pharmaceutical companies leveraging AI in drug discovery and clinical trials, primarily through its Veeva Vault CRM platform. The company has demonstrated strong financial momentum, with net income more than doubling to $714.1 million in FY2025 and operating margins recovering to 25.2% after successfully migrating to its proprietary CRM from Salesforce. This growth is reinforced by recent commitments from major biopharmas, contributing to expected 18% earnings growth this year and 8% EPS growth next, with the stock trading at a 34x forward PE.

Analysis

Veeva Systems (VEEV) is demonstrating strong fundamental momentum and strategic positioning as a critical technology backbone for the life sciences industry's adoption of AI. The company has successfully executed a pivotal transition from a restrictive Salesforce-based CRM to its proprietary Veeva Vault platform. While this migration caused a temporary dip in operating margins to 18.2% in FY2024, they have since recovered strongly to 25.2% in FY2025. This operational shift culminated in a record-setting year, with net income growing 36% to $714.1 million, and the positive trend has continued with the highest-ever quarterly net income of $228.2 million reported. This financial performance is supported by significant client acquisitions, including recent commitments from Bristol Myers Squibb and Gilead, which underscore Veeva's expanding market share and product footprint. From a valuation perspective, the company is projected to grow earnings by 18% this year, with an 8% EPS growth forecast for next year, while trading at a 34x forward P/E multiple. Technically, the stock is in a consolidation phase following a significant breakout in May, with key resistance at $300 and support at $265.

Key Decisions for Investors

• Given the strong fundamental recovery and strategic customer wins, investors could consider initiating or adding to long positions, using a high-volume breakout above the $300 resistance level as a potential confirmation for the next upward move.
• Implement a clear risk management strategy by using the $265 level as a stop-loss, as a break below this support would negate the current bullish consolidation pattern and indicate a need to re-evaluate the position.
• Investors should weigh the company's dominant market position against its forward P/E of 34x and a projected deceleration in EPS growth to 8% next year, which necessitates continued flawless execution to justify the premium valuation.